Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGF

Abstract

Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

1 . (canceled) 
     
     
         2 . A method for treating a macular degeneration patient having previously been treated with a vascular endothelial growth factor (VEGF) inhibitor for about one year, the method comprising administering aflibercept to the patient in an amount of about 2 mg quarterly after the about one year previous treatment with the VEGF inhibitor when the patient has been determined to have one or more of the single nucleotide polymorphisms rs2106124, rs1879796, rs12148845, rs12148100, rs17482885 and rs17629019. 
     
     
         3 . The method of  claim 2 , wherein the single nucleotide polymorphism is rs2106124. 
     
     
         4 . The method of  claim 2 , wherein the single nucleotide polymorphism is rs1879796. 
     
     
         5 . The method of  claim 2 , wherein the single nucleotide polymorphism is rs12148845. 
     
     
         6 . The method of  claim 2 , wherein the single nucleotide polymorphism is rs12148100. 
     
     
         7 . The method of  claim 2 , wherein the single nucleotide polymorphism is rs17482885. 
     
     
         8 . The method of  claim 2 , wherein the single nucleotide polymorphism is rs17629019. 
     
     
         9 . The method of  claim 2 , wherein the aflibercept is formulated for intravitreal administration. 
     
     
         10 . The method of  claim 2 , wherein the patient is heterozygous for at least one of the single nucleotide polymorphisms. 
     
     
         11 . The method of  claim 2 , wherein the patient is homozygous for at least one of the single nucleotide polymorphisms. 
     
     
         12 . The method of  claim 2 , wherein the macular degeneration is age-related wet macular degeneration. 
     
     
         13 . The method of  claim 2 , wherein the previous treatment comprised treatment with a 2 mg dose of aflibercept every 4 weeks. 
     
     
         14 . The method of  claim 13 , wherein the aflibercept is formulated for intravitreal administration. 
     
     
         15 . The method of  claim 13 , wherein the patient is heterozygous for at least one of the single nucleotide polymorphisms. 
     
     
         16 . The method of  claim 13 , wherein the macular degeneration is age-related wet macular degeneration. 
     
     
         17 . The method of  claim 2 , wherein the previous treatment comprised treatment with a 2 mg dose of aflibercept every 8 weeks. 
     
     
         18 . The method of  claim 17 , wherein the aflibercept is formulated for intravitreal administration. 
     
     
         19 . The method of  claim 17 , wherein the patient is homozygous for at least one of the single nucleotide polymorphisms. 
     
     
         20 . The method of  claim 17 , wherein the macular degeneration is age-related wet macular degeneration.